Pharming Group N.V.
Develops and commercializes medicines for rare, debilitating, and life-threatening diseases.
PHARM | AS
Overview
Corporate Details
- ISIN(s):
- NL0010391025 (+1 more)
- LEI:
- 724500DCJ9MPG74JEH91
- Country:
- Netherlands
- Address:
- Darwinweg 24, 2333CR Leiden
- Website:
- https://www.pharming.com/
- Sector:
- Manufacturing
Description
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-03-27 07:50 |
Pharming announces US FDA approval of Joenja® (leniolisib) as the first and onl…
|
English | 300.9 KB | ||
| 2023-03-27 07:50 |
Pharming announces US FDA approval of Joenja® (leniolisib) as the first and onl…
|
English | 309.3 KB | ||
| 2023-03-16 08:14 |
Pharming Group reports financial results for full year 2022
|
English | 561.3 KB | ||
| 2023-03-16 08:14 |
Pharming Group reports financial results for full year 2022
|
English | 561.7 KB | ||
| 2023-03-13 08:42 |
Pharming Group announces that it expects to have full access today to its cash …
|
English | 192.6 KB | ||
| 2023-03-13 08:42 |
Pharming Group announces that it expects to have full access today to its cash …
|
Dutch | 195.6 KB | ||
| 2023-03-13 07:39 |
Pharming Group issues statement regarding the events surrounding Silicon Valley…
|
English | 191.3 KB | ||
| 2023-03-13 07:39 |
Pharming Group issues statement regarding the events surrounding Silicon Valley…
|
English | 190.7 KB | ||
| 2023-02-21 08:12 |
Pharming announces first patient enrolled in pediatric clinical trial of leniol…
|
Dutch | 248.4 KB | ||
| 2023-02-21 08:12 |
Pharming announces first patient enrolled in pediatric clinical trial of leniol…
|
English | 272.2 KB | ||
| 2023-02-16 07:47 |
Pharming provides update on EMA regulatory review of leniolisib for APDS in Eur…
|
Dutch | 219.7 KB | ||
| 2023-02-16 07:47 |
Pharming provides update on EMA regulatory review of leniolisib for APDS in Eur…
|
English | 251.3 KB | ||
| 2022-12-07 09:02 |
Pharming announces publication of data from Phase 3 Study of leniolisib in pati…
|
English | 279.0 KB | ||
| 2022-12-07 09:02 |
Pharming announces publication of data from Phase 3 Study of leniolisib in pati…
|
English | 253.1 KB | ||
| 2022-11-23 08:51 |
Pharming Group announces presentation of new leniolisib data at 2022 ASH Annual…
|
English | 206.8 KB |
Automate Your Workflow. Get a real-time feed of all Pharming Group N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Pharming Group N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Pharming Group N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-05-24 | D.A. Jorn | Non-Executive member | Other | 7,446 | N/A |
| 2023-03-21 | P. Sekhri | Non-Executive member | Other | 9,363 | N/A |
| 2022-10-27 | P. Sekhri | Non-Executive member | Buy | 13,013 | 12,232.22 EUR |
| 2022-10-27 | M. Pykett | Non-Executive member | Buy | 9,760 | 9,174.40 EUR |
| 2022-08-04 | P. Sekhri | Non-Executive member | Buy | 13,013 | 10,000.23 EUR |
| 2022-08-04 | S. Baert | Non-Executive member | Buy | 9,760 | 7,500.36 EUR |
| 2022-05-25 | J. van der Meijs | Non-Executive member | Buy | 9,300 | 86,490,000.00 EUR |
| 2022-05-25 | P. Sekhri | Non-Executive member | Buy | 12,398 | 9,527.62 EUR |
| 2022-05-25 | M. Pykett | Non-Executive member | Buy | 9,300 | 7,146.86 EUR |
| 2022-03-24 | S. de Vries | Non-Executive member | Buy | 318,150 | 232,249.50 EUR |
Peer Companies
